|

CD19 targeted CAR-T cells Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Chongqing Precision Biotech Co., Ltd1

Indications

  • SLE (Systemic Lupus)1
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis1
  • Sjogren's Syndrome1
  • Systemic Scleroderma1
  • Dermatomyositis1

Other1 trial

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.